11.5 Bone marrow aspiration and biopsy will be obtained on Days 
14, 28, and 42 post-transplant for PCR, clonagenic assays and 
FACS analysis. 
11.6 Patients will undergo a restaging evaluation of their known 
sites of metastatic breast cancer one month post transplant. 
Patients with residual disease will be eligible for treatment 
with vinblastine. 
11.7 For patients receiving vinblastine, 1 purple and 1 green top 
tubes will be obtained twice a week to study the presence of 
the neo gene by PCR. Bone marrow aspirates and biopsies will 
be obtained after marrow recovery from cycles 1 and 3 of 
vinblastine to study the effects of chemotherapy and 
hematopoietic growth factors on retroviral marker gene 
expression. 
11.8 Evaluation after Day 60 post-transplantation: Patients will 
return to NCI monthly. Monthly evaluation will induce CBC, 
platelets, differential, electrolytes, liver function tests, BUN, 
creatinine, calcium, albumin, magnesium. Peripheral blood 
samples for PCR analysis will also be obtained (1 green ad 1 
purple top tube). 
11.9 Bone marrow aspirates will be obtained every three months in 
patients whose marrow expresses the neo marker gene. These 
samples will be analyzed for the marker gene by PCR. FACS 
and clonagenic assays will also be performed. 
1 1 .1 OPatients will undergo restaging of their metastatic breast 
cancer every 3-6 months. This will include a CXR every 3 
months and an abdominal, chest CT and bone scan every 6 
months. 
11.11 A creatinine clearance will be obtained prior to hospital 
discharge. 
[ 118 ] 
Recombinant DNA Research, Volume 16 
